Pulmonary Arterial Hypertension and Lung Transplantation

ABSTRACT

Heart–lung transplantation (HLT) and lung transplantation (LT) remain important therapies for idiopathic pulmonary arterial hypertension (IPAH), but recent advances in medical therapy can substantially delay or even obviate the need for transplantation, especially in certain PAH populations. By the early 1990s, the advent of epoprostenol, initially introduced as a bridge therapy to transplantation, in fact resulted in a survival advantage for IPAH. These benefits were comparable to those of HLT, and many patients who were thought to be destined for HLT were subsequently removed from active listing. Since 2005, however, the impact of the new lung allocation score (LAS) on IPAH has increased waiting list mortality. In the new millennium, the balance between the role of available medical therapies for PAH, the existing issues of the current LAS regarding the PAH patient, and the inherent morbidity associated with transplantation of PAH, will be critical to optimizing patient outcomes. The following discussion mainly focuses on adult IPAH, with some reference to congenital heart disease (CHD) and secondary PAH.

KEYWORDS

Pulmonary arterial hypertension - lung transplantation - heart–lung transplantation

REFERENCES

• 1 Reitz B A, Wallwork J L, Hunt S A et al.. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.  N Engl J Med. 1982;  306 557-564
• 2 Magnani B, Galiè N. Prostacyclin in primary pulmonary hypertension.  Eur Heart J. 1996;  17 18-24
• 3 McLaughlin V V. Medical management of primary pulmonary hypertension.  Expert Opin Pharmacother. 2002;  3 159-165
• 4 Chen H, Shiboski S C, Golden J A et al.. Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2009;  180 468-474
• 5 Badesch D B, Champion H C, Sanchez M A et al.. Diagnosis and assessment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2009;  54(1, Suppl) S55-S66
• 6 Simonneau G, Robbins I M, Beghetti M et al.. Updated clinical classification of pulmonary hypertension.  J Am Coll Cardiol. 2009;  54(1, Suppl) S43-S54
• 7 Condliffe R, Kiely D G, Peacock A J et al.. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era.  Am J Respir Crit Care Med. 2009;  179 151-157
• 8 Swanson K L, Wiesner R H, Nyberg S L, Rosen C B, Krowka M J. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups.  Am J Transplant. 2008;  8 2445-2453
• 9 Sitbon O, Humbert M, Nunes H et al.. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.  J Am Coll Cardiol. 2002;  40 780-788
• 10 Orens J B, Estenne M, Arcasoy S Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation et al. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.  J Heart Lung Transplant. 2006;  25 745-755
• 11 Henkens I R, Van Wolferen S A, Gan C T et al.. Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension.  Am J Cardiol. 2009;  103 1451-1456
• 12 Ghio S, Klersy C, Magrini G et al.. Prognostic relevance of the echocardiographic assessment of right ventricular function in patients with idiopathic pulmonary arterial hypertension.  Int J Cardiol. 2008;  , Dec 11. [Epub ahead of print]
• 13 Kawut S M, Horn E M, Berekashvili K K et al.. New predictors of outcome in idiopathic pulmonary arterial hypertension.  Am J Cardiol. 2005;  95 199-203
• 14 Deng Z, Haghighi F, Helleby L et al.. Fine mapping of PPH1, a gene for familial primary pulmonary hypertension, to a 3-cM region on chromosome 2q33.  Am J Respir Crit Care Med. 2000;  161(3 Pt 1) 1055-1059
• 15 Göttmann U, van der Woude F J, Braun C. Endothelin receptor antagonists: a new therapeutic option for improving the outcome after solid organ transplantation?.  Curr Vasc Pharmacol. 2003;  1 281-299
• 16 Lane K B, Machado R D, Pauciulo M W International PPH Consortium et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.  Nat Genet. 2000;  26 81-84
• 17 Loyd J E. Genetics and pulmonary hypertension.  Chest. 2002;  122(6, Suppl) 284S-286S
• 18 Morse J H, Jones A C, Barst R J, Hodge S E, Wilhelmsen K C, Nygaard T G. Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32.  Circulation. 1997;  95 2603-2606
• 19 Austin E D, Cogan J D, West J D et al.. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.  Eur Respir J. 2009;  34 1093-1099
• 20 Morrell N W, Yang X, Upton P D et al.. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins.  Circulation. 2001;  104 790-795
• 21 Abdalla S A, Gallione C J, Barst R J et al.. Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.  Eur Respir J. 2004;  23 373-377
• 22 Mouthon L, Guillevin L, Humbert M. Pulmonary arterial hypertension: an autoimmune disease?.  Eur Respir J. 2005;  26 986-988
• 23 Rabinovitch M. Autoimmune disease and unexplained pulmonary hypertension.  Circulation. 1992;  85 380-381
• 24 Rich S, Kieras K, Hart K, Groves B M, Stobo J D, Brundage B H. Antinuclear antibodies in primary pulmonary hypertension.  J Am Coll Cardiol. 1986;  8 1307-1311
• 25 Negi V S, Tripathy N K, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension.  J Rheumatol. 1998;  25 462-466
• 26 Yoshio T, Masuyama J, Sumiya M, Minota S, Kano S. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus.  J Rheumatol. 1994;  21 2058-2063
• 27 Terrier B, Tamby M C, Camoin L et al.. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  177 1128-1134
• 28 Morse J H, Antohi S, Kasturi K et al.. Fine specificity of anti-fibrillin-1 autoantibodies in primary pulmonary hypertension syndrome.  Scand J Immunol. 2000;  51 607-611
• 29 Morse J H, Barst R J, Fotino M et al.. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.  Am J Respir Crit Care Med. 1997;  155 274-278
• 30 Boin F, Franchini S, Colantuoni E, Rosen A, Wigley F M, Casciola-Rosen L. Independent association of anti-beta(2)-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.  Arthritis Rheum. 2009;  60 2480-2489
• 31 Sanchez O, Marcos E, Perros F et al.. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2007;  176 1041-1047
• 32 Taraseviciene-Stewart L, Nicolls M R, Kraskauskas D et al.. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling.  Am J Respir Crit Care Med. 2007;  175 1280-1289
• 33 Austin E D, Rock M T, Mosse C A et al.. T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension.  Respir Med. 2009;  , Oct 30. [Epub ahead of print]
• 34 Ulrich S, Nicolls M R, Taraseviciene L, Speich R, Voelkel N. Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension.  Respiration. 2008;  75 272-280
• 35 Tuder R M, Groves B, Badesch D B, Voelkel N F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.  Am J Pathol. 1994;  144 275-285
• 36 Wang X X, Zhang F R, Shang Y P et al.. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial.  J Am Coll Cardiol. 2007;  49 1566-1571
• 37 Daley E, Emson C, Guignabert C et al.. Pulmonary arterial remodeling induced by a Th2 immune response.  J Exp Med. 2008;  205 361-372
• 38 Dorfmüller P, Zarka V, Durand-Gasselin I et al.. Chemokine RANTES in severe pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2002;  165 534-539
• 39 Balabanian K, Foussat A, Dorfmüller P et al.. CX(3)C chemokine fractalkine in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2002;  165 1419-1425
• 40 Fartoukh M, Emilie D, Le Gall C, Monti G, Simonneau G, Humbert M. Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension.  Chest. 1998;  114(1, Suppl) 50S-51S
• 41 Humbert M, Monti G, Brenot F et al.. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension.  Am J Respir Crit Care Med. 1995;  151 1628-1631
• 42 Steiner M K, Syrkina O L, Kolliputi N, Mark E J, Hales C A, Waxman A B. Interleukin-6 overexpression induces pulmonary hypertension.  Circ Res. 2009;  104 236-244 , 28p following 244
• 43 Schermuly R T, Dony E, Ghofrani H A et al.. Reversal of experimental pulmonary hypertension by PDGF inhibition.  J Clin Invest. 2005;  115 2811-2821
• 44 Sakao S, Taraseviciene-Stewart L, Cool C D et al.. VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34+precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells.  FASEB J. 2007;  21 3640-3652
• 45 Nickel N, Kempf T, Tapken H et al.. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  178 534-541
• 46 Said S I. The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation.  Ann N Y Acad Sci. 2008;  1144 148-153
• 47 Leuchte H H, Baezner C, Baumgartner R A et al.. Inhalation of vasoactive intestinal peptide in pulmonary hypertension.  Eur Respir J. 2008;  32 1289-1294
• 48 Sakamaki F, Kyotani S, Nagaya N et al.. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy.  Circulation. 2000;  102 2720-2725
• 49 McMurtry M S, Archer S L, Altieri D C et al.. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension.  J Clin Invest. 2005;  115 1479-1491
• 50 Herve P, Humbert M, Sitbon O et al.. Pathobiology of pulmonary hypertension: the role of platelets and thrombosis.  Clin Chest Med. 2001;  22 451-458
• 51 Pietra G G, Capron F, Stewart S et al.. Pathologic assessment of vasculopathies in pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 25S-32S
• 52 Fisher M R, Mathai S C, Champion H C et al.. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension.  Arthritis Rheum. 2006;  54 3043-3050
• 53 Dorfmüller P, Humbert M, Perros F et al.. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases.  Hum Pathol. 2007;  38 893-902
• 54 Overbeek M J, Vonk M C, Boonstra A et al.. Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy.  Eur Respir J. 2009;  34 371-379
• 55 Cool C D, Stewart J S, Werahera P et al.. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.  Am J Pathol. 1999;  155 411-419
• 56 Loscalzo J. Endothelial dysfunction in pulmonary hypertension.  N Engl J Med. 1992;  327 117-119
• 57 Rai P R, Cool C D, King J A et al.. The cancer paradigm of severe pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2008;  178 558-564
• 58 Hoeper M M, Galiè N, Simonneau G, Rubin L J. New treatments for pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2002;  165 1209-1216
• 59 Strauss W L, Edelman J D. Prostanoid therapy for pulmonary arterial hypertension.  Clin Chest Med. 2007;  28 127-142, ix ix
• 60 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 61 D'Alonzo G E, Barst R J, Ayres S M et al.. Survival in patients with primary pulmonary hypertension: results from a national prospective registry.  Ann Intern Med. 1991;  115 343-349
• 62 Sitbon O, Badesch D B, Channick R N et al.. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.  Chest. 2003;  124 247-254
• 63 Rubin L J, Moser K. Long-term effects of nitrendipine on hemodynamics and oxygen transport in patients with cor pulmonale.  Chest. 1986;  89 141-145
• 64 Rubin L J, Nicod P, Hillis L D, Firth B G. Treatment of primary pulmonary hypertension with nifedipine: a hemodynamic and scintigraphic evaluation.  Ann Intern Med. 1983;  99 433-438
• 65 Rich S, Kaufmann E. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing.  J Am Coll Cardiol. 1991;  18 1323-1327
• 66 Sitbon O, Humbert M, Jaïs X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
• 67 Rich S, Brundage B H, Levy P S. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension.  Circulation. 1985;  71 1191-1196
• 68 Mukerjee D, St George D, Coleiro B et al.. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach.  Ann Rheum Dis. 2003;  62 1088-1093
• 69 Cohen M, Edwards W D, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy.  J Am Coll Cardiol. 1986;  7 172-175
• 70 Barst R J, Rubin L J, Long W A The Primary Pulmonary Hypertension Study Group et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.  N Engl J Med. 1996;  334 296-302
• 71 Badesch D B, Tapson V F, McGoon M D et al.. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial.  Ann Intern Med. 2000;  132 425-434
• 72 Rosenzweig E B, Kerstein D, Barst R J. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects.  Circulation. 1999;  99 1858-1865
• 73 Dimopoulos K, Inuzuka R, Goletto S et al.. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension.  Circulation. 2010;  121 20-25
• 74 Simonneau G, Barst R J, Galie N Treprostinil Study Group et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.  Am J Respir Crit Care Med. 2002;  165 800-804
• 75 Lang I, Gomez-Sanchez M, Kneussl M et al.. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.  Chest. 2006;  129 1636-1643
• 76 Tapson V F, Gomberg-Maitland M, McLaughlin V V et al.. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial.  Chest. 2006;  129 683-688
• 77 McLaughlin V, Rubin L, Benza R L, Seeger W. TRIUMPH-I: efficacy and safety of inhaled treprostinil sodium in patients with pulmonary arterial hypertension [abstract].  Am J Respir Crit Care Med. 2009;  117 A965
• 78 Galiè N, Humbert M, Vachiéry J L Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.  J Am Coll Cardiol. 2002;  39 1496-1502
• 79 Sitbon O, Manes A, Jais X et al.. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.  J Cardiovasc Pharmacol. 2007;  49 1-5
• 80 Olschewski H, Simonneau G, Galiè N Aerosolized Iloprost Randomized Study Group et al. Inhaled iloprost for severe pulmonary hypertension.  N Engl J Med. 2002;  347 322-329
• 81 McLaughlin V V, Oudiz R J, Frost A et al.. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2006;  174 1257-1263
• 82 Galiè N, Olschewski H, Oudiz R J Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.  Circulation. 2008;  117 3010-3019
• 83 Rubin L J, Badesch D B, Barst R J et al.. Bosentan therapy for pulmonary arterial hypertension.  N Engl J Med. 2002;  346 896-903
• 84 McLaughlin V V, Sitbon O, Badesch D B et al.. Survival with first-line bosentan in patients with primary pulmonary hypertension.  Eur Respir J. 2005;  25 244-249
• 85 Oudiz R J, Galiè N, Olschewski H ARIES Study Group et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.  J Am Coll Cardiol. 2009;  54 1971-1981
• 86 Galiè N, Brundage B H, Ghofrani H A Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group et al. Tadalafil therapy for pulmonary arterial hypertension.  Circulation. 2009;  119 2894-2903
• 87 Galiè N, Ghofrani H A, Torbicki A Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group et al. Sildenafil citrate therapy for pulmonary arterial hypertension.  N Engl J Med. 2005;  353 2148-2157
• 88 Blanco I, Gimeno E, Munoz P A et al.. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.  Am J Respir Crit Care Med. 2010;  181 270-278
• 89 Ghofrani H A, Wiedemann R, Rose F et al.. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.  Lancet. 2002;  360 895-900
• 90 Glanville A R, Burke C M, Theodore J, Robin E D. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation.  Chest. 1987;  91 675-681
• 91 Sandoval J, Gaspar J, Pulido T et al.. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment.  J Am Coll Cardiol. 1998;  32 297-304
• 92 Allcock R J, O'Sullivan J J, Corris P A. Atrial septostomy for pulmonary arterial hypertension.  Heart. 2003;  89 1344-1347
• 93 Kurzyna M, Dabrowski M, Bielecki D et al.. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension.  Chest. 2007;  131 977-983
• 94 Rich S, Dodin E, McLaughlin V V. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application.  Am J Cardiol. 1997;  80 369-371
• 95 Mereles D, Ehlken N, Kreuscher S et al.. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension.  Circulation. 2006;  114 1482-1489
• 96 Thenappan T, Shah S J, Rich S, Tian L, Archer S L, Gomberg-Maitland M. Contemporary survival in patients with pulmonary arterial hypertension: a reappraisal of the National Institutes of Health Risk Stratification Equation.  Eur Respir J. 2009;  , Dec 23. [Epub ahead of print]
• 97 McLaughlin V V, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.  Circulation. 2002;  106 1477-1482
• 98 Christie J D, Edwards L B, Aurora P et al.. The registry of the international society for heart and lung transplantation: twenty-sixth official adult lung and heart-lung transplantation Report-2009.  J Heart Lung Transplant. 2009;  28 1031-1049
• 99 Egan T M, Murray S, Bustami R T et al.. Development of the new lung allocation system in the United States.  Am J Transplant. 2006;  6(5 Pt 2) 1212-1227
• 100 Kshettry V R, Kroshus T J, Savik K, Hertz M I, Bolman R M. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients.  Chest. 1996;  110 704-709
• 101 Griffith B P, Hardesty R L, Trento A et al.. Heart-lung transplantation: lessons learned and future hopes.  Ann Thorac Surg. 1987;  43 6-16
• 102 Pasque M K, Trulock E P, Kaiser L R, Cooper J D. Single-lung transplantation for pulmonary hypertension: three-month hemodynamic follow-up.  Circulation. 1991;  84 2275-2279
• 103 Pasque M K, Kaiser L R, Dresler C M, Trulock E, Triantafillou A N, Cooper J D. Single lung transplantation for pulmonary hypertension: technical aspects and immediate hemodynamic results.  J Thorac Cardiovasc Surg. 1992;  103 475-481, discussion 481–482
• 104 Pasque M K, Trulock E P, Cooper J D et al.. Single lung transplantation for pulmonary hypertension: single institution experience in 34 patients.  Circulation. 1995;  92 2252-2258
• 105 Katz W E, Gasior T A, Quinlan J J et al.. Immediate effects of lung transplantation on right ventricular morphology and function in patients with variable degrees of pulmonary hypertension.  J Am Coll Cardiol. 1996;  27 384-391
• 106 Fremes S E, Patterson G A, Williams W G, Goldman B S, Todd T R, Maurer J. Toronto Lung Transplant Group . Single lung transplantation and closure of patent ductus arteriosus for Eisenmenger's syndrome.  J Thorac Cardiovasc Surg. 1990;  100 1-5
• 107 Kreitmann B, Metras D, Badier M. Unilateral lung transplantation for Eisenmenger's syndrome.  J Thorac Cardiovasc Surg. 1992;  104 529-530
• 108 Lupinetti F M, Bolling S F, Bove E L et al.. Selective lung or heart-lung transplantation for pulmonary hypertension associated with congenital cardiac anomalies.  Ann Thorac Surg. 1994;  57 1545-1548 discussion 1549
• 109 Levy N T, Liapis H, Eisenberg P R, Botney M D, Trulock E P. Pathologic regression of primary pulmonary hypertension in left native lung following right single-lung transplantation.  J Heart Lung Transplant. 2001;  20 381-384
• 110 Gammie J S, Keenan R J, Pham S M et al.. Single- versus double-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1998;  115 397-402 discussion 403
• 111 Bando K, Armitage J M, Paradis I L et al.. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1994;  108 1056-1065
• 112 Conte J V, Borja M J, Patel C B, Yang S C, Jhaveri R M, Orens J B. Lung transplantation for primary and secondary pulmonary hypertension.  Ann Thorac Surg. 2001;  72 1573-1579 discussion 1579-1580
• 113 Levine S M, Jenkinson S G, Bryan C L et al.. Ventilation-perfusion inequalities during graft rejection in patients undergoing single lung transplantation for primary pulmonary hypertension.  Chest. 1992;  101 401-405
• 114 Birsan T, Zuckermann Z, Artermiou O et al.. Bilateral lung transplantation for pulmonary hypertension.  Transplant Proc. 1997;  29 2892-2894
• 115 Fitton T P, Kosowski T R, Barreiro C J et al.. Impact of secondary pulmonary hypertension on lung transplant outcome.  J Heart Lung Transplant. 2005;  24 1254-1259
• 116 Toyoda Y, Thacker J, Santos R et al.. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension.  Ann Thorac Surg. 2008;  86 1116-1122
• 117 Trulock E P, Edwards L B, Taylor D O, Boucek M M, Keck B M, Hertz M I. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult lung and heart-lung transplant report—2004.  J Heart Lung Transplant. 2004;  23 804-815
• 118 Kuntz C L, Hadjiliadis D, Ahya V N et al.. Risk factors for early primary graft dysfunction after lung transplantation: a registry study.  Clin Transplant. 2009;  , Feb 20. [Epub ahead of print]
• 119 Keshavjee S H, Yamazaki F, Cardoso P F, McRitchie D I, Patterson G A, Cooper J D. A method for safe twelve-hour pulmonary preservation.  J Thorac Cardiovasc Surg. 1989;  98 529-534
• 120 Steen S, Kimblad P O, Sjöberg T, Lindberg L, Ingemansson R, Massa G. Safe lung preservation for twenty-four hours with Perfadex.  Ann Thorac Surg. 1994;  57 450-457
• 121 Sundaresan S, Lima O, Date H et al.. Lung preservation with low-potassium dextran flush in a primate bilateral transplant model.  Ann Thorac Surg. 1993;  56 1129-1135
• 122 Ardehali A, Laks H, Russell H et al.. Modified reperfusion and ischemia-reperfusion injury in human lung transplantation.  J Thorac Cardiovasc Surg. 2003;  126 1929-1934
• 123 Thabut G, Mal H, Cerrina J et al.. Graft ischemic time and outcome of lung transplantation: a multicenter analysis.  Am J Respir Crit Care Med. 2005;  171 786-791
• 124 Sleiman C, Mal H, Fournier M et al.. Pulmonary reimplantation response in single-lung transplantation.  Eur Respir J. 1995;  8 5-9
• 125 Ware L B, Golden J A, Finkbeiner W E, Matthay M A. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation.  Am J Respir Crit Care Med. 1999;  159 980-988
• 126 Prop J, Ehrie M G, Crapo J D, Nieuwenhuis P, Wildevuur C R. Reimplantation response in isografted rat lungs: analysis of causal factors.  J Thorac Cardiovasc Surg. 1984;  87 702-711
• 127 Gammie J S, Cheul Lee J, Pham S M et al.. Cardiopulmonary bypass is associated with early allograft dysfunction but not death after double-lung transplantation.  J Thorac Cardiovasc Surg. 1998;  115 990-997
• 128 Wan S, LeClerc J L, Vincent J L. Cytokine responses to cardiopulmonary bypass: lessons learned from cardiac transplantation.  Ann Thorac Surg. 1997;  63 269-276
• 129 Aeba R, Griffith B P, Kormos R L et al.. Effect of cardiopulmonary bypass on early graft dysfunction in clinical lung transplantation.  Ann Thorac Surg. 1994;  57 715-722
• 130 Chatila W M, Criner G J. Complications of long-term mechanical ventilation.  Respir Care Clin N Am. 2002;  8 631-647
• 131 Khan S U, Salloum J, O'Donovan P B et al.. Acute pulmonary edema after lung transplantation: the pulmonary reimplantation response.  Chest. 1999;  116 187-194
• 132 Palmer S M, Miralles A P, Lawrence C M, Gaynor J W, Davis R D, Tapson V F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: results of a randomized, prospective study.  Chest. 1999;  116 127-133
• 133 Lau C L, Palmer S M, Posther K E et al.. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients.  Ann Thorac Surg. 2000;  69 1520-1524
• 134 Orens J B. Lung transplantation for pulmonary hypertension.  Int J Clin Pract Suppl. 2007;  , Dec (158) 4-9
• 135 Kawaguchi A T, Kawashima Y, Mizuta T et al.. Single lung transplantation in rats with fatal pulmonary hypertension.  J Thorac Cardiovasc Surg. 1992;  104 825-829
• 136 Kawaguchi A T, Mizuta T, Matsuda H et al.. Single lung transplantation in rats with chemically induced pulmonary hypertension.  J Thorac Cardiovasc Surg. 1992;  103 483-489
• 137 Boujoukos A J, Martich G D, Vega J D, Keenan R J, Griffith B P. Reperfusion injury in single-lung transplant recipients with pulmonary hypertension and emphysema.  J Heart Lung Transplant. 1997;  16 439-448
• 138 Bando K, Keenan R J, Paradis I L et al.. Impact of pulmonary hypertension on outcome after single-lung transplantation.  Ann Thorac Surg. 1994;  58 1336-1342
• 139 Ueno T, Smith J A, Snell G I et al.. Bilateral sequential single lung transplantation for pulmonary hypertension and Eisenmenger's syndrome.  Ann Thorac Surg. 2000;  69 381-387
• 140 Chatila W M, Furukawa S, Gaughan J P, Criner G J. Respiratory failure after lung transplantation.  Chest. 2003;  123 165-173
• 141 Thabut G, Vinatier I, Stern J B et al.. Primary graft failure following lung transplantation: predictive factors of mortality.  Chest. 2002;  121 1876-1882
• 142 King R C, Binns O A, Rodriguez F et al.. Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation.  Ann Thorac Surg. 2000;  69 1681-1685
• 143 Whitson B A, Nath D S, Johnson A C et al.. Risk factors for primary graft dysfunction after lung transplantation.  J Thorac Cardiovasc Surg. 2006;  131 73-80
• 144 Prekker M E, Herrington C S, Hertz M I, Radosevich D M, Dahlberg P S. Early Trends in PaO(2)/fraction of inspired oxygen ratio predict outcome in lung transplant recipients with severe primary graft dysfunction.  Chest. 2007;  132 991-997
• 145 Fiser S M, Tribble C G, Long S M et al.. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.  Ann Thorac Surg. 2002;  73 1041-1047, discussion 1047–1048
• 146 Huang H J, Yusen R D, Meyers B F et al.. Late primary graft dysfunction after lung transplantation and bronchiolitis obliterans syndrome.  Am J Transplant. 2008;  8 2454-2462
• 147 Mikhail G, al-Kattan K, Banner N et al.. Long-term results of heart-lung transplantation for pulmonary hypertension.  Transplant Proc. 1997;  29 633
• 148 Bridges N D, Mallory Jr G B, Huddleston C B, Canter C E, Sweet S C, Spray T L. Lung transplantation in children and young adults with cardiovascular disease.  Ann Thorac Surg. 1995;  59 813-820, discussion 820–821
• 149 Keating D, Levvey B, Kotsimbos T et al.. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years.  Transplant Proc. 2009;  41 289-291
• 150 Mendeloff E N, Meyers B F, Sundt T M et al.. Lung transplantation for pulmonary vascular disease.  Ann Thorac Surg. 2002;  73 209-217, discussion 217–219
• 151 Davis Jr R D, Trulock E P, Manley J Washington University Lung Transplant Group et al. Differences in early results after single-lung transplantation.  Ann Thorac Surg. 1994;  58 1327-1334, discussion 1334–1335
• 152 Weiss E S, Allen J G, Merlo C A, Conte J V, Shah A S. Survival after single versus bilateral lung transplantation for high-risk patients with pulmonary fibrosis.  Ann Thorac Surg. 2009;  88 1616-1625, discussion 1625–1626
• 153 Huerd S S, Hodges T N, Grover F L et al.. Secondary pulmonary hypertension does not adversely affect outcome after single lung transplantation.  J Thorac Cardiovasc Surg. 2000;  119 458-465
• 154 Chan K M. Idiopathic pulmonary arterial hypertension and equity of donor lung allocation in the era of the lung allocation score: are we there yet?.  Am J Respir Crit Care Med. 2009;  180 385-387
• 155 Iribarne A, Russo M J, Davies R R et al.. Despite decreased wait-list times for lung transplantation, lung allocation scores continue to increase.  Chest. 2009;  135 923-928
• 156 OPTN/UNOS Thoracic Organ Transplantation Committee .REVEAL Registry presentation: does the LAS score underestimate the risk of death in listed PAH patients?. Available at: http://wwwunosorg/CommitteeReports/interim_main_ThoracicOrganTransplantationCommittee_9_10_2008_16_1pdf 2008
• 157 OPTN/UNOS Thoracic Organ Transplantation Committee .Add factors “current bilirubin” and “change in bilirubin” to the lung allocation score. Available at: http://wwwunosorg/SharedContentDocuments/091023_Exec_Comm_Policy_Noticepdf 2009
• 158 Conte J V, Gaine S P, Orens J B, Harris T, Rubin L J. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.  J Heart Lung Transplant. 1998;  17 679-685
• 159 Badesch D B, Raskob G E, Elliott C G et al.. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry.  Chest. 2009;  , Oct 16. [Epub ahead of print]
• 160 Rich S, Dantzker D R, Ayres S M et al.. Primary pulmonary hypertension: a national prospective study.  Ann Intern Med. 1987;  107 216-223
• 161 Chapelier A, Vouhé P, Macchiarini P et al.. Comparative outcome of heart-lung and lung transplantation for pulmonary hypertension.  J Thorac Cardiovasc Surg. 1993;  106 299-307
• 162 Bîrsan T, Kranz A, Mares P et al.. Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension.  J Heart Lung Transplant. 1999;  18 304-309
• 163 Soriano C M, Gaine S P, Conte J V, Fairman R P, White C, Rubin L J. Anastomotic pulmonary hypertension after lung transplantation for primary pulmonary hypertension: report of surgical correction.  Chest. 1999;  116 564-566
• 164 Izbicki G, Shitrit D, Schechtman I et al.. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation.  J Heart Lung Transplant. 2005;  24 635-637
• 165 de Perrot M, Waddell T K, Chamberlain D, Hutcheon M, Keshavjee S. De novo pulmonary capillary hemangiomatosis occurring rapidly after bilateral lung transplantation.  J Heart Lung Transplant. 2003;  22 698-700
• 166 Chen F, Hanaoka N, Hasegawa S et al.. Right ventricular outflow tract obstruction after bilateral lung transplantation.  Thorac Cardiovasc Surg. 2009;  57 48-50
• 167 Rosas V, Conte J V, Yang S C et al.. Lung transplantation and systemic sclerosis.  Ann Transplant. 2000;  5 38-43
• 168 Pigula F A, Griffith B P, Zenati M A, Dauber J H, Yousem S A, Keenan R J. Lung transplantation for respiratory failure resulting from systemic disease.  Ann Thorac Surg. 1997;  64 1630-1634
• 169 Yeatman M, McNeil K, Smith J A et al.. Lung Transplantation in patients with systemic diseases: an eleven-year experience at Papworth Hospital.  J Heart Lung Transplant. 1996;  15 144-149
• 170 Levine S M, Anzueto A, Peters J I, Calhoon J H, Jenkinson S G, Bryan C L. Single lung transplantation in patients with systemic disease.  Chest. 1994;  105 837-841
• 171 Schachna L, Medsger Jr T A, Dauber J H et al.. Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension.  Arthritis Rheum. 2006;  54 3954-3961
• 172 Kubo M, Vensak J, Dauber J, Keenan R, Griffith B, McCurry K. Lung transplantation in patients with scleroderma.  J Heart Lung Transplant. 2001;  20 174-175
• 173 Massad M G, Powell C R, Kpodonu J et al.. Outcomes of lung transplantation in patients with scleroderma.  World J Surg. 2005;  29 1510-1515
• 174 Rothman A, Sklansky M S, Lucas V W et al.. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension.  Am J Cardiol. 1999;  84 682-686
• 175 Strueber M, Hoeper M M, Fischer S et al.. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device.  Am J Transplant. 2009;  9 853-857
• 176 Khan T A, Schnickel G, Ross D et al.. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.  J Thorac Cardiovasc Surg. 2009;  138 1417-1424